A61P 3 - Drugs for disorders of the metabolism

Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
10/2006
10/18/2006	CN1280292C Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
10/18/2006	CN1280291C Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
10/18/2006	CN1280290C Novel glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
10/18/2006	CN1280288C Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
10/18/2006	CN1280275C Pyridione derivatives for tretment of atherosclerosis
10/18/2006	CN1280269C Aliphatic nitrogenous five-membered ring compounds
10/18/2006	CN1280266C Acylphenylurea derivatives, a process for their preparation and their use as pharmaceuticals
10/18/2006	CN1279970C Extermal weight reduction drug through adjusting incretion
10/18/2006	CN1279965C Traditional Chinese medicine preparation for treating cranial vascular diseases, its preparation method and application
10/18/2006	CN1279955C Medicine tea for curing diabetes
10/18/2006	CN1279949C Chinese medicine for fat reducing and long life
10/18/2006	CN1279946C Medicinal wine and its producing method
10/18/2006	CN1279944C Medicine for treating cardiocerebral vascular system disease and blood supply deficiency, medicine preparing method and preparation
10/18/2006	CN1279918C Energy-supplementing saccharide source and its uses
10/18/2006	CN1279905C Enteric migelinai agent and its preparation method
10/18/2006	CN1279904C Vitamin C composition containing sodium vitamin C
10/18/2006	CN1279844C Nutritional supplement to treat macular degeneration
10/18/2006	CN1279843C Dietary compositions and methods
10/17/2006	US7122680 3-Substituted oxindole β3 agonsists
10/17/2006	US7122679 Multicyclic compounds and the use thereof
10/17/2006	US7122677 NK1 antagonists
10/17/2006	US7122665 Heterocyclic compounds
10/17/2006	US7122635 Method and composition for angiogenesis inhibition
10/17/2006	US7122567 Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity
10/17/2006	US7122556 Phenylalanine enamide derivatives
10/17/2006	US7122555 Pyrido [2,1-a] isoquinoline derivatives
10/17/2006	US7122551 Metalloproteinase inhibitor compounds
10/17/2006	US7122547 Anthranilic acid amides and the use thereof as medicaments
10/17/2006	US7122544 Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
10/17/2006	US7122543 Substituted benzoic acid derivatives having NF-κB inhibiting action
10/17/2006	US7122534 Aryl fused azapolycyclic compounds
10/17/2006	US7122530 24-hydroxyvitamin D, analogs and uses thereof
10/17/2006	US7122517 Crystallized structure of type IV collagen NC1 domain hexamer
10/17/2006	US7122357 Administering mixture of lipolytic, proteolytic and amylolytic enzymes such as pancreatin
10/17/2006	US7122344 Production of recombinant human uteroglobin (rhUG) for use as a therapeutic in the treatment of inflammation and fibrotic diseases. The invention provides processes, including bacterial expression and protein purification and scaled
10/17/2006	US7122327 Utilization of mass spectrometry to elucidate particular biopolymer markers indicative or predictive of a particular disease state, and most particularly to specific biopolymer markers whose up-regulation, down-regulation, or relative presence in disease vs. normal states
10/17/2006	US7122213 Composed of squash extract mixed with onion extract, having hypotensive effect and an anti-diabetic effect
10/17/2006	US7122209 Oral compositions for the treatment of non-diabetic obese mammals, including humans
10/17/2006	US7122187 Treating autoimmune diseases with humanized anti-CD40L antibody
10/17/2006	US7122177 Preparation and xenotransplantation of porcine islets
10/17/2006	CA2447405C Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
10/17/2006	CA2318527C Inhibitors of .alpha.4 mediated cell adhesion
10/17/2006	CA2293808C Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases
10/17/2006	CA2241856C Agent for prophylaxis and treatment of diabetic complications
10/17/2006	CA2196880C Nervonic acid compositions
10/17/2006	CA2126305C New treatments using venlafaxine
10/12/2006	WO2006108008A2 A method and composition for nutritionally improving glucose control and insulin action
10/12/2006	WO2006107902A2 Use of spirostenols to treat mitochondrial disorders
10/12/2006	WO2006107661A1 Histamine h3 receptor agents, preparation and therapeutic uses
10/12/2006	WO2006107561A1 Tetrahydrothiopyrano pyrazole cannabinoid modulators
10/12/2006	WO2006107062A2 Benzimidazole derivative and use as angiotensin ii antagonist
10/12/2006	WO2006107059A1 Medicine for renal perfusion disorder
10/12/2006	WO2006106926A1 Lignane compound-containing oil-in-water emulsion and composition comprising the same
10/12/2006	WO2006106887A1 Edible composition containing component extracted from salix sp. extract
10/12/2006	WO2006106805A1 Method of improving the storage stability of substance
10/12/2006	WO2006106372A1 New crystalline atorvastatin hemicalcium salt polymorph form
10/12/2006	WO2006106054A1 Pyridine-3-carboxamide derivatives as cb1 inverse agonists
10/12/2006	WO2006106052A1 Pyrazoles
10/12/2006	WO2006105913A1 Tripeptides that down regulate the activity of plasma membrane transporters including sodium-d-glucose cotransporter sglt1
10/12/2006	WO2006105912A2 Peptides that down regulate the activity of plasma membrane transporters including sodium-d-glucose cotransporter sglt1
10/12/2006	WO2006105850A1 Acyl hydrazides as kinase inhibitors, in particular for sgk
10/12/2006	WO2006105643A1 Stabilized pharmaceutical compositions comprising an hmg-coa reductase inhibitor
10/12/2006	WO2006047516A3 Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
10/12/2006	WO2006005667A3 Polypeptide protracting tags comprising a tetrazole moiety
10/12/2006	US20060229470 Calcium receptor-active molecules
10/12/2006	US20060229363 Substituted Heteroaryl- and Phenylsulfamoyl Compounds
10/12/2006	US20060229301 To treat inflammatory diseases, immune diseases like autoimmune diseases or allergic diseases, or HIV infection; chemokine receptor antagonists; safe and low-toxic; 1-butyl-3-isobutyl-1,3,8-triazaspiro[4.5]decane-2,4-dione
10/12/2006	US20060229298 Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
10/12/2006	US20060229296 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl-2-(4-hydroxy-phenyl])-3-methyl-1H-indol-5-ol, or salts for treating bone loss
10/12/2006	US20060229286 Therapy of diabetes
10/12/2006	US20060229281 Cycloalkyl-Hydroxyl Compounds and Compositions for Cholesterol Management and Related Uses
10/12/2006	US20060229236 Cyclic tetrapeptide compound and use thereof
10/12/2006	US20060228432 alpha-glucosidase inhibitors from a natural source
10/12/2006	DE102005015254A1 New indazole derivatives are serum and glucocorticoid regulated kinase inhibitors useful to treat and/or prevent e.g. diabetes, cardiovascular diseases, fibrosis and inflammatory diseases
10/12/2006	CA2604861A1 Stabilized pharmaceutical compositions comprising an hmg-coa reductase inhibitor
10/12/2006	CA2603475A1 Acyl hydrazides as kinase inhibitors, in particular for sgk
10/12/2006	CA2603452A1 Tripeptides that down regulate the activity of plasma membrane transporters including sodium-d-glucose cotransporter sglt1
10/12/2006	CA2603347A1 Oil-in-water emulsions of lignans that exhibit improved absorption rate
10/12/2006	CA2603127A1 Use of spirostenols to treat mitochondrial disorders
10/12/2006	CA2603104A1 Tetrahydrothiopyrano pyrazole cannabinoid modulators
10/12/2006	CA2602787A1 Pyridine-3-carboxamide derivatives as cb1 inverse agonists
10/12/2006	CA2602624A1 Benzimidazole derivative and use as angiotensin ii antagonist
10/12/2006	CA2602234A1 Histamine h3 receptor agents, preparation and therapeutic uses
10/12/2006	CA2601427A1 A method and composition for nutritionally improving glucose control and insulin action
10/11/2006	EP1710307A2 RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
10/11/2006	EP1710231A1 CETP activity inhibitors
10/11/2006	EP1709975A1 Tablet and process for producing the same
10/11/2006	EP1709071A1 Glucagon-like peptide-1 analogs with long duration of action
10/11/2006	EP1709049A1 Bicyclic imidazole compounds, the production thereof and their use as medicaments
10/11/2006	EP1709035A1 1 , 3 - dioxane derivatives and analogues thereof useful in the treatment of i.a. obesity and diabetes
10/11/2006	EP1709014A1 Antidiabetic oxazolidinediones and thiazolidinediones
10/11/2006	EP1709000A1 Piperidine derivatives as gcs inhibitors
10/11/2006	EP1708994A1 Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics
10/11/2006	EP1708726A1 Formulation for treating obesity and associated metabolic syndrome
10/11/2006	EP1708723A1 Method of treating hyperphosphataemia using lanthanum hydroxycarbonate
10/11/2006	EP1708716A2 Oral dieting composition comprising conjugated linoleic acid and caffeine
10/11/2006	EP1708711A1 Compositions useful especially for treatment or prevention of metabolic syndrome
10/11/2006	EP1708698A1 3-(4-piperidine-1ylmethyl-phenyl)-propion acid-phenylamide-derivatives and related compounds used in the form of mch antagonists (melanine concentrating hormone) for treating eating disorders
10/11/2006	EP1708695A1 Compositions and method for treatment of steroid/nuclear receptor-mediated diseases
10/11/2006	EP1608235B1 A process for preparation of hypoglycemic foods and formulations thereof

1 ... 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 ... 1298